The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity. The main question it aims to answer is:
- Can a combination of a digi-physical treatment tool and obesity medication improve treatment outcomes for patients with obesity compared to patients treated with obesity medications alone?
This is a randomized controlled two-arm multicenter study where participants will be randomized to the intervention group (digi-physical treatment+medication) or control group (medication only). Participants will be followed for six months.

Start Date13 Feb 2026

Sponsor / Collaborator

Karolinska Institutet

[+1]

NCT07337174

/ Not yet recruitingPhase 1

A Randomized, Open-label, Single Dose, Two-way, Crossover, Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects

The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.

Start Date25 Jan 2026

Sponsor / Collaborator

Huons Co., Ltd.

100 Clinical Results associated with Liraglutide

100 Translational Medicine associated with Liraglutide

100 Patents (Medical) associated with Liraglutide

4,725

Literatures (Medical) associated with Liraglutide

31 Dec 2026·ANNALS OF MEDICINE

GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers

Review

Author: Chikatimalla, Rahul ; Aggarwal, Kanishk ; Perry, Griffin ; Shah, Twinkle ; Shah, Ashka ; Banker, Himanshi ; Jain, Rohit

OBJECTIVES:

To evaluate the current evidence supporting the cerebrovascular protective effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in individuals with type 2 diabetes mellitus (T2DM), and to outline their mechanisms of action in stroke prevention.

METHODS:

A narrative review was conducted by synthesising data from cardiovascular outcome trials, meta-analyses and mechanistic studies involving GLP-1RAs such as semaglutide, liraglutide and dulaglutide. The search included literature on ischaemic stroke incidence, molecular pathways and clinical outcomes associated with GLP-1RA therapy.

RESULTS:

GLP-1RAs exhibit multiple protective mechanisms, including anti-inflammatory, antioxidant, neuroprotective and endothelial-stabilising effects. Long-acting agents demonstrate superior efficacy in reducing nonfatal and ischaemic stroke risk, with relative risk reductions ranging from 15% to 39% across major trials. These benefits are observed independent of glycemic control and appear most prominent in patients with preserved renal function and shorter diabetes duration. In contrast, short-acting exendin-based GLP-1RAs show limited cerebrovascular benefit. Treatment response may vary based on factors such as stroke subtype, baseline vascular risk and comorbidities.

CONCLUSION:

GLP-1RAs offer significant promise as adjunctive pharmacotherapy for stroke prevention in individuals with T2DM. Their multifactorial benefits extend beyond glucose regulation and may influence clinical outcomes through systemic vascular and neuroprotective mechanisms. However, inconsistencies in trial outcomes and limited data in non-diabetic or high-risk populations underscore the need for targeted stroke-specific studies. Personalised treatment approaches and broader risk stratification may optimise their use in cerebrovascular disease management.

01 Dec 2026·MOLECULAR BIOLOGY REPORTS

Mechanisms and therapeutic strategies of ferroptosis in Diabetic-Associated Cognitive Dysfunction: focus on the crosstalk with apoptosis, autophagy, and pyroptosis

Review

Author: Jiang, Yayi ; Zhou, Jianlong ; Yue, Rensong ; Shi, Wenxiang

Diabetes-associated cognitive dysfunction (DACD), a serious central nervous system complication of diabetes mellitus, poses a heavy global burden due to its intricate pathogenesis and lack of effective therapies. Mounting evidence identifies programmed cell death (PCD) as a pivotal driver of DACD progression. This review systematically elaborates on the molecular mechanisms of various PCD modalities (including apoptosis, autophagy, pyroptosis, and ferroptosis) in DACD, with a particular focus on the role of ferroptosis as a core pathogenic mechanism. Hyperglycemia disrupts cerebral iron homeostasis, induces mitochondrial dysfunction and oxidative stress, leading to inhibition of glutathione peroxidase 4 (GPX4) activity and accumulation of lipid peroxides. This cascade ultimately triggers ferroptosis in neurons, glial cells, and the blood-brain barrier, resulting in impaired synaptic plasticity and cognitive decline. Furthermore, the review delineates the complex interactive regulatory network between ferroptosis and other PCD forms (e.g., autophagy, pyroptosis), which can converge into the coordinated cell death program of PANoptosis. Intervention strategies targeting ferroptosis, such as iron chelators (deferoxamine), antioxidants (N-acetylcysteine), GPX4 activators, natural products (resveratrol, curcumin), repurposed traditional medicines (liraglutide, metformin), and non-pharmaceutical interventions (exercise, electroacupuncture), have demonstrated significant potential in improving cognitive function in preclinical models. This review aims to provide novel insights into the pathophysiology of DACD and establish a theoretical foundation for developing precise therapeutic strategies centered on targeting ferroptosis.

01 Aug 2026·JOURNAL OF AFFECTIVE DISORDERS

Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study

Article

Author: Aboukaoud, Mohammed ; Hoch, Bosmat ; Amiaz, Revital ; Weiser, Mark

INTRODUCTION:

Evidence regarding depression and suicidality with glucagon-like peptide-1 receptor agonists (GLP-1RAs) remains inconsistent, particularly in patients with type 2 diabetes mellitus (T2DM) and underlying affective vulnerability.

METHODS:

We conducted a disproportionality analysis of the WHO VigiBase (2010-2024), including T2DM patients. Reports of depressed mood and suicidal thoughts associated with GLP-1RAs were compared with other glucose-lowering medications. Analyses incorporated age, sex, time-to-onset, dose, comorbid depression, and concomitant antidepressant use. Adjusted reporting odds ratios (RORs) and a Weibull time-to-event model were applied. Causality was explored using Bradford Hill criteria.

RESULTS:

A total of 1,183,817 adverse events related to GLP-1RA were identified. Depressed mood and suicidality signals were observed with semaglutide, liraglutide, and tirzepatide (adjusted ROR_0.25: 2.13, 1.52, 1.07) and (adjusted ROR_0.25: 6.76, 2.43, 3.39), respectively. No signal was identified for suicide attempts or completed suicide. Absolute reporting frequencies were low. Concomitant antidepressant use was 2.3-5 times more frequent, and comorbid depression 25%-120% higher, compared with other glucose-lowering medications. Median time-to-onset was 96 days. Survival analysis demonstrated an early increase in reporting followed by stabilization over time. Adjustment for antidepressant use modestly attenuated associations.

CONCLUSION:

GLP-1RAs were associated with increased reporting of depressed mood and suicidal thoughts, particularly in patients receiving concomitant antidepressants. These findings support a patient-centered model in which underlying affective vulnerability or reporting factors drive reported mood symptoms rather than a uniform drug-specific effect. GLP-1RAs remain clinically valuable, but psychiatric monitoring during early treatment in vulnerable patients is warranted.

396

News (Medical) associated with Liraglutide

22 May 2026

·www.fiercepharma.com

Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm

A CHMP recommendation for AstraZeneca’s novel cancer drug Etcamah was one of several positive decisions for drugmakers at this week's meeting. Less than a month after an FDA advisory committee voted 6-3 to reject AstraZeneca’s camizestrant, Europe’s Committee for Medicinal Products for Human Use (CHMP) has blessed it with a positive opinion. The European experts have recommended that the oral SERD treatment can be used in combination with a CDK4/6 inhibitor for patients with ER-positive, HER2-negative locally advanced or metastatic breast cancer if they have ESRI mutations.Last month, the FDA’s Oncologic Drugs Advisory Committee (ODAC) raised questions about the design of the pivotal SERENA-6 study, which showed a 56% improvement in progression-free survival (PFS) for switching to camizestrant, used on top of a CDK4/6 inhibitor, compared with continuing treatment with an aromatase inhibitor (AI) and a CDK4/6 drug.The FDA took issue with AZ’s study, arguing it did not address whether this first-line switch approach provides long-term benefit to patients compared with the standard practice of waiting until disease progression to use a new therapy. Although camizestrant extended median PFS by 6.8 months in the trial design, the FDA was unsure of its clinical meaningfulness.The FDA has not yet issued its decision on the drug, though it usually sides with the recommendations provided by their expert committees. In Europe, the drug will carry the brand name Etcamah. Europe signs off on Novo’s Wegovy pill The CHMP also endorsed Novo Nordisk’s Wegovy pill, clearing it for approval to become the first oral GLP-1 treatment for obesity in Europe. The arrival of the Wegovy pill comes as other drugmakers are developing their investigational oral weight-loss treatments. Last month, Eli Lilly gained approval in the United States for its obesity pill Foundayo. The Indianapolis company has yet to submit for approval of its pill in Europe. The FDA signed off on oral Wegovy in January and the company reported its first quarter sales at $355 million.While injected Wegovy can be used by patients age 12 and older, the European recommendation for the oral version covers adults only. The daily pill must be taken on an empty stomach, after an eight hour fast, followed by 30 more minutes without food, drink or any other medications. The nod was backed by a trial of 307 adults who were obese or overweight, with participants losing an average of 14% of their body weight compared to a 2% figure for those on placebo. The CHMP also signed off on two versions of Novo-developed GLP-1 liraglutide, which are now sold by German generics specialist Stada. The positive opinions were issued for obesity treatment Ablymico, which is a hybrid version of Novo’s Saxenda, and for Liraglutide Stada, which contains the same active substance of Novo’s Victoza. New drugs gain CHMP nods The CHMP has put its stamp of approval on Boehringer Ingelheim’s Jascayd for two lung disorders—idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The nod comes two months after Boehringer Chairman Shashank Deshpande expressed frustration over the regulatory timelines in Europe.“Why is that possible in one jurisdiction or territory and why does it take six months, nine months in Europe?" Deshpande asked. Jascayd is the first new treatment in more than a decade for IPF, a potentially fatal disorder that causes a buildup of scar tissue in the lungs and limits oxygen intake. As a selective phosphodiesterase-4B (PDE4B) inhibitor, Jascayd brings a new mechanism of action to the market. The FDA approved Jascayd for IPF in October of last year and two months later followed with an expansion to treat PPF.Meanwhile, Novartis has scored a CHMP nod for Vijoice, an oral drug that treats the rare disorder PIK3CA-related overgrowth spectrum (PROS). The endorsement comes four years after the FDA approved the treatment, which is the first of its kind to address the underlying cause of the condition. The CHMP green light covers patients age 2 and older. Additionally, a month after the FDA rejected a novel aesthetic product from AbbVie, the CHMP has signed off on it for glabellar frown lines following local muscular paralysis. The U.S. regulator gave the fast-acting follow-on to its blockbuster Botox a thumbs down because of a manufacturing snafu. The injected treatment works for two to three weeks, often giving patients confidence to move onto longer-acting Botox. NICE does a 180 on Genmab’s Tivdak Over in the United Kingdom, the National Institute for Health and Care Excellence (NICE) has reversed its opinion on Genmab’s cancer treatment Tivdak, now recommending (PDF) its use by the National Health Service (NHS) for those with recurrent or metastatic cervical cancer who have had disease progression despite earlier systemic therapy.England’s Medicines and Healthcare Products Regulatory Agency (MHRA) approved Tivdak in the indication December of last year. But two months ago, in its initial guidance, NICE questioned its cost-effectiveness, saying it was “higher than the range normally considered acceptable.”

Drug ApprovalAccelerated ApprovalClinical Result

21 May 2026

·www.sciencedaily.com

A huge international review found that GLP-1 weight-loss drugs significantly reduce the risk of heart attacks, strokes, heart failure, and premature death over the long term. Researchers say these medications could become a major weapon against cardiovascular disease — not just obesity and diabetes.New research suggests that GLP-1 weight loss medications may provide major long-term benefits for heart health in addition to helping people lose weight and manage blood sugar. Researchers at Anglia Ruskin University (ARU) reviewed data from more than 90,000 participants involved in large international clinical trials. Their analysis found that people taking glucagon-like peptide-1 (GLP-1) receptor agonists had a significantly lower risk of serious cardiovascular problems compared with those who received a placebo. The findings were published in Cardiovascular Diabetology -- Endocrinology Reports. Long-Term Heart Protection Confirmed The researchers examined results from 11 major cardiovascular outcome trials that followed patients for at least one year. On average, participants were monitored for nearly three years. Across the studies, GLP-1 receptor agonists reduced the risk of major adverse cardiovascular events by about 13%. These events included heart attack, stroke, and death related to cardiovascular disease. The analysis is particularly important because it focused on the drugs' long-term effects rather than short-term outcomes. Researchers also found the cardiovascular benefits were present regardless of whether patients had diabetes. People taking the medications were also less likely to die from any cause during the studies. In addition, rates of non-fatal heart attacks, non-fatal strokes, and hospitalizations for heart failure were all lower among patients using the drugs. Benefits Seen in High-Risk Patients The strongest benefits were observed in individuals already considered at high cardiovascular risk, including people with obesity, type 2 diabetes, or existing heart disease. GLP-1 receptor agonists include widely used medications such as semaglutide, liraglutide, and dulaglutide. These drugs have gained enormous attention in recent years because of their effectiveness in treating obesity. The review found no meaningful increase in serious safety risks compared with placebo, including severe hypoglycemia or acute pancreatitis. However, gastrointestinal side effects such as nausea and vomiting remained more common, which researchers noted is already well understood with these medications. Researchers Say the Findings Could Shape Future Healthcare Lead author Dr. Simon Cork, Physiology lead at Anglia Ruskin University's School of Medicine, said: "This is the most comprehensive review to date of long-term cardiovascular outcome trials for GLP-1 receptor agonists. We know that one of the factors that weighs on people's minds when considering going onto these drugs is the potential long-term side effects. "Our results show that, when taken over a prolonged period of at least one year, these medications do much more than help control blood sugar or weight. They significantly reduce the risk of heart attacks, strokes and premature death in people who are already vulnerable. "We found the benefits to be consistent across different drugs, trial designs and patient groups. This has important implications for clinical practice and health policy, particularly given cardiovascular disease is the leading cause of death in the UK. "These drugs have the potential to become a key part of healthcare strategies, especially for people with type 2 diabetes or established heart disease. Using them earlier and more widely across populations could help prevent thousands of serious cardiovascular events."

AHA

19 May 2026

·www.prnewswire.com

Two Pharma Companies Now Own Nearly 100% of GLP-1 Citations Inside ChatGPT, Claude and Perplexity, New 5W Index Finds

Five GLP-1 brands capture 57% of all AI citations in the $150 billion weight loss and metabolic health category; legacy programs and supplements losing visibility in real time NEW YORK, May 19, 2026 /PRNewswire/ -- Two pharmaceutical companies — Novo Nordisk and Eli Lilly — now own nearly 100% of GLP-1 citations inside the AI tools where Americans research weight loss, according to The Weight Loss & Metabolic Health AI Visibility Index 2026, released today by 5W, the premier AI communications and GEO firm in the United States. The index ranks the top 25 U.S. brands in the weight loss and metabolic health category by their share of citations across ChatGPT, Claude, Perplexity and Google AI Overviews. It is the fourth installment in 5W's AI Visibility Index series, following editions on Legal Tech, Real Estate and Fintech. Five GLP-1 receptor agonists — Wegovy, Zepbound, Ozempic, Mounjaro and Saxenda — together capture roughly 57% of all category citations. The four leading brands alone capture 55%. Novo Nordisk and Eli Lilly are the only sources of FDA-approved options for chronic weight management and the only sources of the peer-reviewed clinical trial data — STEP, SURMOUNT and SELECT — that AI models cite as evidence. The Top 15 by AI Citation Share: Wegovy — 19.0% Zepbound — 16.0% Ozempic — 13.0% Mounjaro — 7.0% Noom — 7.0% WeightWatchers — 7.0% MyFitnessPal — 6.0% Lose It! — 3.0% Cronometer — 2.0% Simple — 2.0% Saxenda — 2.0% Factor — 1.5% Optavia — 1.5% Jenny Craig — 1.0% Nutrisystem — 1.0% The remaining ~11% of citation share is split across ranks 16–25 and unranked brands. Telehealth providers and compounded-medication marketplaces are excluded from this edition and will be covered in a forthcoming index. The Citation Compounding Dynamic The index identifies clinical trial publication as the highest-leverage citation event in the category. Zepbound's recent trajectory illustrates the dynamic. SURMOUNT-5, the head-to-head trial against Wegovy published in 2025, demonstrated superior weight loss for tirzepatide. That single data point is now cited in nearly every "Wegovy vs Zepbound" AI answer, and the citation itself has driven prescription volume. "Two pharmaceutical companies now own nearly 100% of GLP-1 citations in AI answers. Six pharma brands take roughly 58% of the entire category. That is not a market share story. It is a marketing infrastructure story," said Ronn Torossian, founder of 5W. "Novo Nordisk and Eli Lilly built the citation moat the same way every other category leader will eventually have to build it: peer-reviewed clinical data, named-author editorial coverage, regulatory events treated as content events, and a content cadence faster than the news cycle. AI citation share is the scoreboard. Most brands in this category are not yet playing." Pivots, Moats and Collapse The index identifies three winning playbooks and three losing categories. Behavioral programs Noom and WeightWatchers have pivoted into the GLP-1 era with very different financial outcomes but similar citation outcomes. Noom's 2022 launch of Noom Med positioned the company as "behavioral change plus medication access," and AI now cites it as the category's hybrid default. WeightWatchers filed Chapter 11 in 2025 and emerged with a GLP-1-centric strategy, but its citation share has held because of more than 60 years of accumulated brand equity and editorial coverage. MyFitnessPal, owned by Francisco Partners, is cited in an estimated 60–70% of "best diet app" AI answers. Its 15-year head start on food-database construction and 200 million-plus user base create an informational moat that newer apps cannot displace through product quality alone. The losers: legacy behavioral brands (Jenny Craig, Nutrisystem, Optavia) are increasingly framed in AI answers as "before GLP-1s, people tried...". Meal delivery is being recategorized as an adjunct to medication-based weight loss. The OTC supplement category — Hydroxycut, Leanbean, PhenQ and Garcinia products — has lost nearly all generic citation share to GLP-1s and Plenity, with AI models flagging supplement claims with evidence caveats. Methodology 5W analyzed more than 60 common consumer prompts across five sub-categories — pharmaceutical GLP-1s, behavioral programs, diet and nutrition apps, packaged meal services, and supplements — running each through ChatGPT, Claude, Perplexity and Google AI Overviews in Q1 2026. Citation sources tracked include WebMD, Healthline, GoodRx, the NIH, Mayo Clinic, Forbes Health, U.S. News Health, Reddit, CNBC, Bloomberg, STAT News and FiercePharma. The index is a marketing and communications research document. It does not rank products on clinical effectiveness, safety or appropriateness, and does not constitute medical advice. Download The full index, including the methodology, the top 15 ranking, six structural truths, six 2026 dynamics and the 10-point Weight Loss Marketer Playbook, is available as an ungated PDF at: 5wpr.com/research/weight-loss-ai-visibility-index-2026 About 5W 5W is the AI Communications Firm — building brand authority across the platforms where decisions now happen: ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews, alongside earned media, digital, and influencer channels. 5W combines public relations, digital marketing, Generative Engine Optimization (GEO), and proprietary AI visibility research to help clients measure and grow their presence in AI-driven buyer research. Founded in 2002, 5W is recognized as a Top U.S. PR Agency by O'Dwyer's, named Agency of the Year in the American Business Awards®, honored as a 2026 Top Place to Work in Communications by Ragan, and named to Digiday's WorkLife Employer of the Year list. 5W serves clients across B2C sectors — Beauty & Fashion, Consumer Brands, Entertainment, Food & Beverage, Health & Wellness, Travel & Hospitality, Technology, and Nonprofit — and B2B specialties including Corporate Communications, Reputation Management, Public Affairs, Crisis Communications, and Digital Marketing across Social, Influencer, Paid Media, GEO, and SEO. Learn more at 5wpr.com Media Contact Chris Bergin [email protected] SOURCE 5W Public Relations 21% more press release views with Request a Demo

100 Deals associated with Liraglutide

External Link

KEGG	Wiki	ATC	Drug Bank
-	Liraglutide	A10BJ02	DB06655

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	United States	Novo Nordisk, Inc.	23 Dec 2014
Overweight	United States	Novo Nordisk, Inc.	23 Dec 2014
Diabetes Mellitus, Type 2	European Union	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	Iceland	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	Liechtenstein	Novo Nordisk A/S	30 Jun 2009
Diabetes Mellitus, Type 2	Norway	Novo Nordisk A/S	30 Jun 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cerebrovascular Disorders	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Chronic heart failure	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Coronary Disease	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Peripheral Vascular Diseases	Phase 3	Germany	Novo Nordisk A/S	01 Nov 2020
Polycystic Ovary Syndrome	Phase 3	United States	Novo Nordisk A/S	26 Sep 2018
Binge-Eating Disorder	Phase 3	United States	Novo Nordisk A/S	29 Sep 2017
Prader-Willi Syndrome	Phase 3	United States	Novo Nordisk A/S	09 Nov 2015
Prader-Willi Syndrome	Phase 3	Australia	Novo Nordisk A/S	09 Nov 2015
Prader-Willi Syndrome	Phase 3	Canada	Novo Nordisk A/S	09 Nov 2015
Prader-Willi Syndrome	Phase 3	France	Novo Nordisk A/S	09 Nov 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01794143 (GRADE, CTgov)	Phase 3	Diabetes Mellitus, Type 2	7,850	Glargine Insulin (Glargine Insulin U-100)	rpbfeptsth(ktdyxevuxq) = josesgyhsc pqtsldietr (kovpdfaxre, jirswlbpno - icfmquueso) View more	-	10 Feb 2026
				Glimepiride (Glimepiride)	rpbfeptsth(ktdyxevuxq) = lkhlwywxqk pqtsldietr (kovpdfaxre, xddqroqjcg - cefrawkjon) View more
NCT04122716 (Pubmed \| Sports Med)	Phase 3	Obesity	193	Liraglutide (Exercise)	cnxujugefk(yewutoqnjt) = telqqvrjcd modyhteoam (pqaxcqrgis, 0.5 - 5.5)	Positive	24 Jan 2026
				Liraglutide alone	zltkoovspb(uxbapcznvl) = zercjbnghy wjwsqxxrmr (haiqaothwm )
NCT03948347 (LAMP, Pubmed \| JAMA Intern Med) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Ischemic Attack, Transient \| Acute Ischemic Stroke	636	Liraglutide	purzxpxygh(jifbfhfbxi) = uymjkdsros nqfnuayjgg (ucvwcrlfhd ) View more	Positive	03 Nov 2025
				Control	purzxpxygh(jifbfhfbxi) = vujeugfdkh nqfnuayjgg (ucvwcrlfhd ) View more
NCT03260881 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Coronary Artery Disease	38	liraglutide (Study Group)	ujmfbzbptf(jxgnawiviw) = quqtepovdc jrptdjctnl (parpidqmwr, 0.60) View more	-	08 Jul 2025
				placebo (Control Group)	ujmfbzbptf(jxgnawiviw) = eketaohefw jrptdjctnl (parpidqmwr, 2.3) View more
NCT02516657 (CTgov)	Phase 3	Diabetes Mellitus, Type 1	5	Liraglutide	qmiuvbabyd(hzmspnqnmn) = nrpxqoeibz fpyuapyrlm (zexfetjukw, 35) View more	-	20 Apr 2025
NCT04881110 (STARDUST, CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Peripheral Arterial Disease	60	Liraglutide (Liraglutide Group)	xokgyesdrz(gezqkiiexr) = bskciwbfcg bapawlewxa (iaoygndnzw, 5.9) View more	-	03 Mar 2025
				Control (Control Group)	xokgyesdrz(gezqkiiexr) = cvvpqfhmtw bapawlewxa (iaoygndnzw, 4.8) View more
ASCO_GU2025	Phase 3	Prostatic Cancer	-	GLP-1 receptor agonists (GLP-1RAs)	qhstraepir(kbrmyggaxo) = mlrerwbzcl mhvosxpwmo (cewnzmltvd )	Negative	13 Feb 2025
				Placebo/non-GLP-1 RA regimens	qhstraepir(kbrmyggaxo) = ddwcjlizmw mhvosxpwmo (cewnzmltvd )
Pubmed Manual	Not Applicable	Overweight \| Obesity	15,491	Tirzepatide 15 mg once weekly	qnchihhtry(tbkgcoodux) = tickunadqk ufktdgiuqa (qujpzxbqgz )	Positive	07 Jan 2025
				Semaglutide 2.4 mg once weekly	qnchihhtry(tbkgcoodux) = yciurysmtr ufktdgiuqa (qujpzxbqgz )
NCT02098395 \| NCT01836523 (ADJUNCT ONE and ADJUNCT TWO, Pubmed \| J Diabetes Sci Technol)	Phase 3	Diabetes Mellitus, Type 1 C-peptide	-	Liraglutide 1.8 mg	sitrcxhxqc(nwdqqqfoaz) = bfbwtbugrs sbbxpzrtxt (fvoileurmd ) View more	-	24 Dec 2024
				Liraglutide 1.2 mg	sitrcxhxqc(nwdqqqfoaz) = lscbvckzva sbbxpzrtxt (fvoileurmd ) View more
NCT06439056 (NEWS)	Phase 1	Diabetes Mellitus, Type 2	3	利拉鲁肽-NEX-22A	yuiismbsxp(kfxrggqpcs) = Clinical results have reached the endpoint duyatkxfem (oxhkgjsdyf ) View more	Positive	22 Nov 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis